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Background: Ginkgo biloba extract (GbE) is used extensively by breast cancer patients undergoing treatment with
Tamoxifen (TAM). Thus, the present study investigated the effects of GbE in female Sprague–Dawley (SD) rats
bearing chemically-induced mammary tumors and receiving TAM.
Methods: Animals bearing mammary tumors (≥1 cm in diameter) were divided into four groups: TAM [10 mg/kg,
intragastrically (i.g.)], TAM plus GbE [50 and 100 mg/kg, intraperitoneally (i.p.)] or an untreated control group. After
4 weeks, the therapeutic efficacy of the different treatments was evaluated by measuring the tumor volume (cm3)
and the proportions of each tumor that were alive, necrotic or degenerative (mm2). In addition, labeling indexes
(LI%) were calculated for cell proliferation (PCNA LI%) and apoptosis (cleaved caspase-3 LI%), expression of
estrogen receptor-alpha (ER-α) and p63 biomarkers.
Results: Overall, the tumor volume and the PCNA LI% within live tumor areas were reduced by 83% and 99%,
respectively, in all TAM-treated groups when compared to the untreated control group. GbE treatment (100 mg/kg)
reduced the proportions of live (24.8%) and necrotic areas (2.9%) (p = 0.046 and p = 0.038, respectively) and
significantly increased the proportion of degenerative areas (72.9%) (p = 0.004) in mammary tumors when compared
to the group treated only with TAM. The expression of ER-α, p63 and cleaved caspase-3 in live tumor tissues was not
modified by GbE treatment.
Conclusions: Co-treatment with 100 mg/kg GbE presented a slightly beneficial effect on the therapeutic efficacy of
TAM in female SD rats bearing mammary tumors.
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Mammary carcinogenesisBackground
The majority of breast cancers are estrogen-dependent
disease with increasing morbidity and mortality rates in
most western societies over the last few decades [1-3].
The most common therapeutic strategies for breast cancer,
including excision surgery (mastectomy), radiotherapy,
chemotherapy, monoclonal antibodies and endocrine ther-
apies, impact on women’s quality of life [4]. As an endo-
crine adjuvant therapy, anti-estrogenic drugs target the
estrogen receptor (ER)-dependent intracellular response by
directly binding to and inhibiting ERs (Selective Estrogen
Receptor Modulators, SERMs) or by down-regulating the* Correspondence: barbisan@ibb.unesp.br
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reproduction in any medium, provided the orsynthesis of endogenous estrogens (Aromatase Inhibitors,
AIs) [5,6]. The SERMs, which include TAM and Raloxifen,
have been established as gold standard first-line therapies
for estrogen-dependent breast cancers [7]. TAM has been
found to reduce the incidence of breast cancer in high-risk
pre- and post-menopausal women and to enhance disease-
free survival and reduce disease recurrence [8]. However,
an extensive evaluation of TAM use has revealed some side
effects such as increased risk for endometrial cancer, deep-
vein thrombosis and pulmonary embolism [9-11]. These
important side effects have resulted in the use of alterna-
tive treatments such as complementary and alternative
medicine (CAM).
Popular interest in CAM has grown rapidly over the past
decade in the western world [12]. Commercial advertise-
ments, many of which promise cures, have stimulated the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and nutritional supplements. The use of CAM is more
common among cancer patients than among the general
population [12]. Recent reports estimate that 7-64% of
chemotherapy patients in 26 cohort studies worldwide
have used herbal supplements [13,14], and up to 72% of
these patients did not inform their physician about their
concomitant CAM usage [15]. Although the use of herbal
or ‘natural’ drugs is rapidly growing, most of these promis-
ing therapies remain poorly understood, and limited scien-
tific evidence regarding their efficacy and safety is available
[16]. Thus, preclinical and clinical studies are necessary to
evaluate the safety and efficacy of each CAM alone and/or
in combination with prescription drug therapies.
Ginkgo biloba extract (GbE) is a well-established medi-
cinal herb extensively used as a CAM in diseases includ-
ing breast cancer [17]. GbE is a complex mixture of over
300 compounds primarily composed of flavonoid glyco-
sides and terpenoids such as ginkgolides and bilobalides
[17,18]. GbE has been used for the prevention and treat-
ment of brain disorders, systemic circulatory disorders,
memory loss and Alzheimer’s disease [17,19,20]. In fact,
many molecules within GbE have been shown to exhibit
pharmacological properties such as cell cycle regulatory,
antioxidant, anti-proliferative, anti-angiogenic and anti-
estrogenic activities [21]. As GbE is used extensively as a
CAM [17] and is used by breast cancer patients under-
going treatment with TAM [22], the present study was
designed to investigate the effects of Ginkgo biloba ex-
tract in a chemically induced mammary tumor model in
female SD rats treated with Tamoxifen.
Methods
Animals and treatments
The animals used in this study were handled in accord-
ance with the ethical principles for animal research
adopted by the Brazilian College of Animal Experimenta-
tion (COBEA). The protocols used here were approved
by the Botucatu School of Medicine Ethical Committee for
Animal Research (protocol no. 51/08- Commission of Eth-
ics in Animal Experimentation, CEEA). Four-week-old fe-
male Sprague–Dawley (SD) rats were purchased from
CEMIB-UNICAMP (Campinas- SP, Brazil). All of the ani-
mals were housed in polypropylene cages (four animals/
cage) covered with metallic grids in a room maintained at
22 ± 2°C and 55 ± 10% humidity with a 12-hr light–dark
cycle. Food and water consumption were measured twice a
week, and the animals were weighed once a week during
the entire 4-week treatment period.
Tamoxifen citrate (TAM, NolvadexW) was purchased
from AstraZeneca UK Limited (Macclesfield, Cheshire,
UK). The covered tablets were grasped in a melting pot, di-
luted in canola oil (3 mg/ml) and then orally administered
at dose of 10 mg/kg [23]. Ginkgo biloba leaf extract (GbE,code 500821) was purchased from CentroFlora Group
(Botucatu-SP-Brazil). GbE was obtained by hydroalcoholic
extraction using a spray dryer system and contained
24% flavone glycosides (i.e., quercetin, kaempferol and
isorhamnetin) and 6% terpene trilactones (i.e., bilobalide
and ginkgolide A, B and C) as evaluated by High Perform-
ance Liquid Chromatography (HPLC) [24]. GbE was pre-
diluted in a 10% ethanol-water solution and heated for
3 min at 40°C to evaporate the ethanol. GbE was adminis-
tered intraperitoneally at doses of 50 and 100 mg/kg, which
correspond to approximately 10x the therapeutic dose in
humans [25].
Experimental procedures and tissue processing
At 51 days of age, female SD rats were given a sin-
gle dose of 7,12-dimethyl-benz(a)anthracene (DMBA,
80 mg/kg, i.g.) [24]. Female SD rats bearing palpable mam-
mary tumors (≥1 cm in diameter) were randomly allocated
into four groups (10 rats/group): TAM-treated (10 mg/kg,
i.g.), TAM plus GbE-treated (50 mg/kg, i.p.), TAM plus
GbE-treated (100 mg/kg, i.p.) and TAM vehicle plus GbE
vehicle-treated (canola oil and water, respectively).
Immediately before the beginning of treatments, all
animals bearing palpable tumors were submitted to ex-
cision biopsies under sodium pentobarbital anesthesia
(30 mg/kg, i.p.). The excision biopsies were performed to
evaluate the histopathological pattern of the tumor cell
proliferation and apoptosis indexes and the expression of
estrogen receptor α (ER-α) and p63. After 4 weeks of
treatment, the animals were euthanized with CO2, and
blood samples were collected for the analysis of alanine
aminotransferase (ALT, U/l) and estradiol (E2, pg/ml)
using Ortho-Clinical Diagnostics Reagents (Johnson &
Johnson Co., SP, Brazil). The liver, kidneys, ovaries and
tumor samples were collected during necropsy, fixed in
4% formalin, embedded in paraffin, sectioned at 5 μm
and stained with hematoxylin-eosin (HE) for histopatho-
logical analysis. The biopsies (collected at the beginning
of the experiment) and tumor samples (collected at nec-
ropsy) were immunohistochemically stained for prolifer-
ating cell nuclear antigen (PCNA), cleaved caspase-3,
ER-α and p63.
Measurements of mammary tumor volume and area
Mammary tumors were measured macroscopically in
three dimensions using a caliper rule and their volume
(cm3) was calculated according to the ellipsis volume
formula: 3/4π × width × thickness × depth [26]. All
tumor measures were obtained under sodium pento-
barbital anesthesia at the beginning of the experiment,
immediately before the excision biopsy, and after the
4-week treatment period. The rates of tumor growth
were determined by calculating the difference between
the final and initial volumes.
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HE staining slides and the sizes of live, degenerative and
necrotic areas were measured within the total tumor
area [27]. This analysis was performed at 200x magnifica-
tion using a Nikon photomicroscope (Microphot-FXA)
connected to a KS-300 apparatus (Kontron Elektronic,
Germany). The percentual area fraction of live, degenera-
tive and necrotic areas in the representative sections cut
through the middle of the tumor were estimated by div-
iding the size of each tissue area by the total tumor sec-
tion volume [27]. The total mammary tumor section
areas were measured using a special Macro-Stand device
(support with Canon TV zoom lens V6×16/16-100 mm
plus a Canon 58 mm close-up 240 lens connected to a
CCD black-and-white video camera module with a Sony
DC-777 camera unit) connected to a KS-300.
Immunohistochemical procedure for PCNA, caspase-3,
ER-α and p63
The deparaffinized 5 μm serial mammary tumor sections
on poly-L-lysine-coated slides were first subjected to anti-
gen retrieval by heating the slides in 0.01 M citrate buffer
(pH 6.0) in a pressure cooker (Pascal, DakoCytomation,
USA) or a microwave (3 × 5 min). Endogenous peroxidase
was blocked with 3% H2O2 in phosphate-buffered saline
(PBS) and nonspecific binding was blocked with 3% nonfat
milk. The slides were then incubated overnight at 4°C with
the following primary antibodies: mouse monoclonal anti-
ER-α (clone 6F11, BioCare Medical–Concord, CA, USA,
1:50 dilution), mouse monoclonal anti-p63 (clone 4A4,
DakoCytomation, Denmark A/S, Glostruo, Denmark, 1:75
dilution), mouse monoclonal anti-PCNA (clone PC10,
DakoCytomation Denmark A/S, Glostrup, Denmark, 1:200
dilution) or rabbit polyclonal anti-cleaved caspase-3
(clone Asp 175 rabbit, Cell Signaling Technology, Inc.,
Danvers, MA, USA 1:100 dilution). The slides were then
incubated with a biotinylated secondary anti-mouse anti-
body (Vector Laboratories, Inc., Burlingame, CA, USA,
1:200 dilution) and streptavidin-biotin-peroxidase solution
(TissuGnost Kit, Merck, Darmstadt, Germany, 1:1:50 dilu-
tion). Chromogen color development was accomplished
by 3,3-diaminobenzidine-tetrahydrochroride (DAB, Sigma-
Aldrich Co., St. Louis MO, USA) local precipitation at the
sites of peroxidase binding to the mammary tumor sam-
ples. Finally, the slides were counterstained with Harris’
hematoxylin, dehydrated and analyzed by optical micros-
copy. Negative controls for all of the immunoreactions
were processed in adjacent sections by omitting the incu-
bation with the primary antibodies.
The cell proliferation (PCNA LI%) and apoptosis
(cleaved caspase-3 LI%) indexes and the expression of es-
trogen receptor-α (ER-α) and p63 (myoepithelial cells)
were determined by calculating the percentage of PCNA+,
cleaved caspase-3+, ER-α+ and p63+ cells among the totalnumber of in 10–20 random microscopic fields analyzed
in each tumor (~135 cells/field). All of these immuno-
histochemical analyses were performed in the live tumor
tissues.
Statistical analysis
The statistical analysis was performed using Jandel Sigma
Stat software (Jandel Corporation, San Rafael, CA, USA).
The data were analyzed by ANOVA when the results
showed a normal distribution or by the Kruskal-Wallis
test when they did not. Differences among the groups
were analyzed by the Tukey or Student-Newman-Keuls
methods. Biopsies were compared with tumors by
performing t-tests for dependent variables. Differences
were defined as statistically significant when p < 0.05.
Results
General observations
Food and water consumption (data not shown), body
weight gain, relative liver, kidney and ovarian weights
and serum levels of ALT and E2 did not differ among
the different groups after 4 weeks of treatment with
TAM and/or GbE (Table 1). The liver, kidney and ovar-
ies did not present significant histopathological alter-
ations associated with the different treatments (data not
shown).
Mammary tumor volume and morphometric analyzes
Figure 1A shows the mammary tumor volume before
and after 4 weeks of treatment. All TAM-treated groups
presented a significant reduction in mammary tumor
volume at the end of the treatment period compared
to the untreated control group (p < 0.001) (Table 1,
Figure 1A). The mean volume of the tumors in all of
the TAM-treated groups was reduced by approximately
83% after treatment, whereas the mean volume of the
tumors in the untreated control group increased by
178.7% during the treatment period. Co-treatment with
either dose of GbE (50 or 100 mg/kg) did not signifi-
cantly affect the mammary tumor regression induced
by short-term TAM treatment (Table 1, Figure 1A).
Also, some non-palpable tumors were detected at nec-
ropsy, as follows: 02 tumors in the TAM alone group
and 02 tumors in TAM + GbE50 group.
The histopathological analysis showed that almost all
DMBA-induced mammary tumors (>90%) were invasive
adenocarcinomas presenting predominantly tubular or
papillary patterns (data not shown). The morphometric
measurements of live/degenerative/necrotic areas of
mammary tumors at the end of the treatment period are
shown in Figure 1B and representative images of these
histological areas are presented in Figure 2. Mammary
tumors from the untreated control group showed a high
proportion of live area (80.8%), a moderate proportion
Table 1 General parameters in the experimental groups after 4 weeks of treatment1
Experimental groups3
Parameters2 (G1)TAM (G2) TAM + GbE50 (G3) TAM + GbE100 (G4) Untreated control
General parameters
Animal number (n) 10/94 10/7 10/7 10/5
Tumor number (n) 115 9 9 7
Initial body weight (g) 267.67 ± 3.25 257.25 ± 4.89 261.80 ± 7.89 283.0 ± 2.83
Final body weight (g) 291.33 ± 4.18 287.17 ± 7.99 287.17 ± 4.40 293.40 ± 3.71
Body weight gain (g) 23.43 ± 5.46 31.17 ± 4.71 28.80 ± 9.75 20.0 ± 7.93
Liver relative weight (g) 5.13 ± 0.57 4.38 ± 0.46 4.15 ± 0.67 4.53 ± 0.24
Left ovarian relative weight (mg) 20.0 ± 6.0 17.0 ± 2.64 13.01 ± 2.64 19.0 ± 3.12
Right ovarian relative weight (mg) 19.0 ± 5.0 13.0 ± 3.01 19.01 ± 5.56 17.0 ± 1.78
Initial tumor volume (cm3) 2.23 ± 0.49 2.64 ± 0.93 1.95 ± 0.46 2.09 ± 0.82
Final tumor volume (cm3) 0.85 ± 0.41* 0.83 ± 0.47* 0.57 ± 0.12* 4.73 ± 1.45
Biochemical dosage
ALT (u/l) 37.17 ± 3.59 47.83 ± 4.24 47.0 ± 5.47 35.75 ± 7.68
E2 (ρg/ml) 57.80 ± 4.42 42.83 ± 3.24 34.0 ± 6.34 38.0 ± 6.65
1Data are expressed as mean ± SEM; 2ALT, Alanine amino transferase; E2, Estradiol; 3TAM, Tamoxifen (10 mg/Kg, i.p.); GbE50-100, Ginkgo biloba extract (50 or
100 mg/Kg, i.p.); 4 The difference between initial and final number of rats/group was due to the dead or sacrifice of moribund animals (05 animals in untreated
group) or development of mammary tumor with less than 5% of positivity for ER-α (01 and 03 animals in TAM alone and TAM + GbE50 respectively) or complete
regression of tumors (03 animals in TAM + GbE100). 5 Two animals from each group presented two mammary tumors before the beginning of treatments.
*Statistical difference when compared to the untreated group, p < 0.001.
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(0.5%) (Figure 1B). The group receiving TAM alone
presented a clear change in the morphometric pattern of
mammary tumor areas compared to the untreated con-
trol group, with 48.8% live, 1.5% necrotic and 36.3% de-
generative areas. Co-treatment with 100 mg/kg GbE
reduced the proportions of live (24.8%) and necrotic
areas (2.9%) (p = 0.046 and p = 0.038, respectively) and
significantly increased the proportion of degenerative
area (72.9%) (p = 0.004) compared to the group treated
only with TAM.
Immunohistochemical analysis of cell proliferation,
apoptosis, ER-α and p63
All markers were analyzed within the live areas of mam-
mary tumors at the beginning (referential biopsies) and
at the end of treatments period (Figures 3 and 4). The
differential expression of PCNA, cleaved caspase-3, ER-α
and p63 between referential biopsies at the initial and
the tumors at the end of the treatments is shown in
Figure 3. A significant reduction in the PCNA labeling
index (PCNA LI%) was observed in all TAM-treated
groups compared to the respective referential biopsies
taken at the beginning of the treatment period. The
PCNA LI% within the live tumor areas was significantly
higher in mammary tumors from the untreated control
group (≥6%) than in those from the TAM-treated groups
(≤1%) (p <0.005). Moreover, co-administration of either
dose of GbE did not change the anti-proliferative effectof TAM treatment. Similarly, GbE treatment did not
affect the expression of ER-α, p63 and cleaved caspase-3
in live tumor tissues compared to the group receiving
TAM alone.
Discussion
The present results indicate that the anti-tumoral pro-
perties of Tamoxifen (TAM) were slightly modified by
co-treatment with Ginkgo biloba extract (GbE) in a
DMBA-induced model of mammary carcinogenesis in
female Sprague–Dawley rats. Similar to the findings of
previous in vitro, animal and human cohort studies, we
found that oral treatment with TAM induced an anti-
tumoral effect characterized by significant mammary
tumor regression [6,8,11,23,27,28]. We detected signifi-
cant reductions in mammary tumor volume, in pro-
portion of living tumor tissue, and in frequency of
proliferating cells as indicated by PCNA staining in all
TAM-treated groups (G1, G2 and G3). Proliferating cell
nuclear antigen (PCNA) is a 36 kDa molecule that acts
as a DNA polymerase co-factor during chromosome
replication and is easily detected during S-phase of the
cell cycle [29]. Therefore, PCNA is widely used as a
reliable cell proliferation biomarker in experimental
models of chemical carcinogenesis, including models of
rat mammary carcinogenesis [24,29,30]. In the present
study, the reduced PCNA LI% observed in TAM-treated
rats can be explained by the ability of TAM to inhibit
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Figure 1 Analysis of mammary tumor volume (before and after treatments) and tumor live, degenerative or necrotic areas (after
treatments): (A) Mammary tumor volume at beginning of treatments (referential biopsies) and following 4 weeks of treatment with
tamoxifen and Gingko biloba extract (tumors). TAM = tamoxifen (10 mg/kg, i.p.); GbE 50-100 = Ginkgo biloba extract (50 or 100 mg/kg, i.g.).
(B) Results of morphometric analysis of the proportion of the tumor tissue defined as live (%), degenerative (%) and necrotic (%) areas in all
experimental groups after 4 weeks of treatment with tamoxifen and Gingko biloba extract. *,** Different from untreated control group and TAM
alone group, 0.01 < p < 0.05), respectively.
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mg/kg GbE did not alter the anti-proliferative effect of
TAM in ER-α-positive live tumor tissues, demonstrating
that GbE does not compete with TAM for ER binding by
acting as an ER agonist or antagonist.
Estrogens play a key role in hormone-sensitive breast
cancer cells and their receptors are functional targets of
anti-endocrine therapies for breast cancer [32]. Recent cell
proliferation assays on MCF-7 cells have demonstrated that
extracts of Ginkgo biloba have dual effects on endogenousestrogens, as they can act as either agonists or antagonists
[33,34]. These pharmacological properties depend on the
GbE dose (10–1000 μg/ml) and the concentration of en-
dogenous estrogens present in the cell culture medium
[33,34]. The abundant phytoestrogens present in GbE can
bind with high affinity to ER, establishing an antagonistic
competition with endogenous estrogens such as estradiol
(E2) [33,35-37]. Human studies have also shown that both
phytoestrogens within GbE and SERMs can antagonize the
binding of endogenous estrogens to ERs, increasing the
Figure 2 HE-stained mammary tumor samples at the end of the experimental protocol: (A) mammary tumor border region showing
live and degenerative areas, 200x; (B) live mammary tumor area showing numerous dark basophilic nuclei in epithelial cells
surrounding an apoptotic cell (arrow), 1000x; (C) degenerative mammary tumor area characterized by flattened epithelia and robust














































Figure 3 Immunohistochemical analysis of PCNA (LI%), cleaved caspase-3 (LI%), estrogen receptor-alpha (ER-α, LI%) and p63 (LI%)
staining at beginning (referential biopsies) and at the end of the 4-week treatment period (mammary tumors) with tamoxifen and
Gingko biloba extract. Data are expressed as the mean ± SEM. TAM = tamoxifen (10 mg/kg, i.p.); GbE 50-100 = Ginkgo biloba extract (50 or 100
mg/kg, i.g.). *Significant difference compared to groups G1, G2 and G3, p < 0.005).
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Figure 4 Representative images from immunohistochemical staining of live tumor areas showing immunoreactivity for PCNA (400x),
cleaved caspase-3 (1000x), ER-α (400x) and p63 (400x).
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study, we observed a significant change in the histological
pattern of mammary tumor areas in rats that received
TAM plus 100 mg/kg GbE. This group presented a signifi-
cant increase in the size of degenerative tumor areas to-
gether with a reduction in live tumor areas compared to
the group receiving only TAM. Although this beneficial ef-
fect was observed in rats that received GbE co-treatment,
no changes in E2 serum levels were observed, indicating an
absence of negative feedback induction. Otherwise, the en-
hanced tumor regression observed in these rats may be as-
sociated with the enhanced bioavailability of TAM when
co-administered with quercetin or quercetin-containing
dietary supplements such as GbE [38].
The results of the present study showed that treatment
with TAM and GbE for 4 weeks induced an outstanding
decrease in tumor volume, but complete regression of
the tumor was not accomplished. Indeed, islands of ER-
α-positive tumor cells remained viable in all TAM-
treated groups, suggesting that tumor recurrence would
occur upon termination of the treatment. Recent in vitro,
in vivo and human studies have reported de novo or ac-
quired resistance to SERMs and AIs [39,40]. TAM itself
demonstrates a dual agonist/antagonist activity that results
in a weak estrogenic effect, precluding a total blockade of
estrogen-stimulated tumor growth [41] and driving the
natural selection of TAM-resistant tumor cells [42]. These
live areas within mammary tumors display some intrinsicmechanisms that can partially explain their growth in spite
of ER signaling, such as increased expression of EGFR
and/or HER2 [43]. The cross-talk between ER signaling
and growth factor signaling proteins has been proposed to
be important for the resistance of tumor cells to endocrine
therapies [44]. The overexpression of growth factors and
kinase proteins could thus induce an ER-dependent prolif-
eration response in the absence of ER ligands [45].
Caspases are cysteinyl-aspartate specific proteases that
belong to the C14 family [46]. The proteolytic cleavage
of caspase-2, 3, 6, 7, 8, 9 and 10 in the cytoplasm is dir-
ectly associated with the regulation and execution of
apoptosis [47]. Indeed, cleaved caspase-3 is one of the
most commonly used biomarkers for the detection of
apoptosis in cell culture and animal and human tissues
[48]. In the present study, the cleaved caspase-3 labeling
index (cleaved caspase-3 LI%) was not altered by TAM
treatment in live tumor areas (i.e., islands of ER-α-posi-
tive tumor cells). Therefore, the mode of action of
TAM-induced tumor regression in the present study
might be mainly related to the ability of TAM to prevent
the ER-dependent tumor cells from receiving a prolifera-
tion stimulus rather than inducing cell death in mam-
mary tumors. Nevertheless, other in vivo studies have
demonstrated that different doses of TAM administered
for different periods of time display anti-proliferative prop-
erties associated with the induction of apoptosis [49]. In
addition, co-treatment with 50 mg/kg or 100 mg/kg GbE
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treated with TAM, demonstrating that GbE did not affect
the anti-proliferative action of TAM. Some in vivo studies
have detected protective anti-apoptotic effects of Ginkgo
biloba, but these studies were performed in settings other
than cancer [50-53].
p63 is a p53 analogue protein expressed in the nuclei of
basal cells such as the myoepithelial cells present in mam-
mary tissue, skin, oral cavity, prostatic and urothelial
epithelia [54]. Overexpression of p63 has been frequently
observed in squamous cell carcinomas in humans, sugge-
sting that it may function as an oncogene [55]. Indeed,
in vitro bioassays have demonstrated that gene silencing of
some p63 variants modulates the transcription of genes
regulated by p53 [54]. Recent studies have demonstrated
that the function of myoepithelial cells is strongly associ-
ated with the aggressiveness and invasiveness of human
breast cancer [56]. Treatment with TAM plus GbE did
not affect p63 expression in live tumor tissues in the
present study.
Various in vitro and in vivo studies suggest that Ginkgo
biloba itself has cancer chemopreventive properties, but
epidemiological findings are sparse and inconclusive
[21,35,57-60]. Thus, the findings of the present study in-
dicate that 4 weeks of treatment with 100 mg/kg GbE
had a slightly beneficial effect on the therapeutic efficacy
of TAM in female Sprague–Dawley rats bearing mam-
mary tumors.
Conclusions
Co-administration of GbE during tumor regression in fe-
male SD rats receiving TAM was investigated. While
TAM induced a robust regression of mammary tumors,
GbE had only a slightly additional effect on the anti-
tumor efficacy of TAM. Thus, sustained use of GbE by
breast cancer patients undergoing treatment with TAM
might to safe and/or promote some clinical efficacy.
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